{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T04:15:57Z","timestamp":1746072957904,"version":"3.40.4"},"reference-count":10,"publisher":"Japanese Society of Internal Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Jpn. Soc. Intern. Med.","J. Jpn. Soc. Intern. Med"],"published-print":{"date-parts":[[2012]]},"DOI":"10.2169\/naika.101.993","type":"journal-article","created":{"date-parts":[[2013,5,9]],"date-time":"2013-05-09T22:57:25Z","timestamp":1368140245000},"page":"993-999","source":"Crossref","is-referenced-by-count":1,"title":["3. Pathological Roles of Vasopressin in Water Metabolism: Vasopressin Agonist and Antagonists","3\uff0e\u30d0\u30bd\u30d7\u30ec\u30b7\u30f3\uff08AVP\uff09\u306e\u7570\u5e38\u3068\u305d\u306e\u6cbb\u7642\u2015AVP\u88fd\u5264\uff0cAVP\u53d7\u5bb9\u4f53\u62ee\u6297\u85ac"],"prefix":"10.2169","volume":"101","author":[{"given":"San-e","family":"Ishikawa","sequence":"first","affiliation":[{"name":"Department of Medicine, Jichi Medical University Saitama Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Ishikawa S, Schrier RW: Pathophysiological roles of arginine vasopressin and aquaporin-2 in impaired water excretion. Clin Endocrinol (Oxf) 58: 1-17, 2003.","DOI":"10.1046\/j.1365-2265.2003.01647.x"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Yamamura Y, et al: Characterization of a novel aquaretic agent OPC-31260, as an orally effective, nonpeptide vasopressin V<sub>2<\/sub> receptor antagonist. Br J Pharmacol 105: 787-791, 1992.","DOI":"10.1111\/j.1476-5381.1992.tb09058.x"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Yamamura Y, et al: OPC-41061, a highly potent human vasopressin V<sub>2<\/sub> receptor antagonist: Pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 287: 860-866, 1998.","DOI":"10.1016\/S0022-3565(24)37873-5"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Macion-Dazard R, et al: Mapping the binding site of six nonpeptide antagonists to the human V<sub>2<\/sub>-renal vasopressin receptor. J Pharmacol Exp Ther 316: 564-571, 2006.","DOI":"10.1124\/jpet.105.095554"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Saito T, et al: Hypotonicity reduces the activity of murine aquaporin-2 promoter induced by dibutyryl cAMP. Exp Physiol 93: 1147-1156, 2008.","DOI":"10.1113\/expphysiol.2008.042663"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Saito T, et al: Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J Clin Endocrinol Metab 82: 1054-1057, 1997.","DOI":"10.1210\/jc.82.4.1054"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Schrier RW, et al: Tolvaptan, a selective oral vasopressin V<sub>2<\/sub> receptor antagonist, for hyponatremia. N Engl J Med 355: 2099-2112, 2006.","DOI":"10.1056\/NEJMoa065181"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Berl T, et al: Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 21: 705-712, 2010.","DOI":"10.1681\/ASN.2009080857"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Gheorghiade M, et al: Effects of tolvaptan, a vasopressin antagonist, in patients with hospitalized with worsening heart failure. JAMA 291: 1963-1971, 2004.","DOI":"10.1001\/jama.291.16.1963"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Konstam MA, et al: Effects of oral tolvaptan in patients hospitalized for worsening heart failure. JAMA 297: 1319-1331, 2007.","DOI":"10.1001\/jama.297.12.1319"}],"container-title":["Nihon Naika Gakkai Zasshi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/naika\/101\/4\/101_993\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T09:25:33Z","timestamp":1746005133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/naika\/101\/4\/101_993\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.2169\/naika.101.993","relation":{},"ISSN":["0021-5384","1883-2083"],"issn-type":[{"type":"print","value":"0021-5384"},{"type":"electronic","value":"1883-2083"}],"subject":[],"published":{"date-parts":[[2012]]}}}